Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.62 |
| ▸ | SLC18A2 | Q05940 | 2/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.53 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8557816 | 0.86 | SLC6A2 (0.70) | SLC6A3SLC6A2SLC6A4CHRM2CHRM4 | |
| SCHEMBL6829116 | 0.79 | SLC6A3 (0.74) | SLC6A3SLC6A2SLC6A4SLC18A2 | |
| SCHEMBL10595156 | 0.78 | SLC18A3 (0.64) | — | |
| SCHEMBL6923257 | 0.77 | SLC6A2 (1.00) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6923261 | 0.77 | SLC6A2 (1.00) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7521262 | 0.73 | SLC6A2 (0.58) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7494007 | 0.73 | SLC6A2 (0.58) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL17486623 | 0.73 | SLC18A2 (1.00) | SLC6A3SLC18A2CHRM2CHRM4CHRM5 | |
| SCHEMBL4021371 | 0.73 | ALDH1A1 (0.41) | — | |
| SCHEMBL4024531 | 0.73 | ALDH1A1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1404682-B1 | METHOD OF INHIBITING PTP 1B AND/OR T-CELL PTP AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 | NOVO NORDISK AS (DK) | 2005-09-14 | — | — | EP | disclosed |
| EP-1404682-A1 | METHOD OF INHIBITING PTP 1B AND/OR T-CELL PTP AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 | Novo Nordisk A/S (DK) | 2004-04-07 | — | — | EP | disclosed |
| US-20030064979-A1 | Method of inhibiting PTP 1B and /or T-cell PTP and/or other PTPases with an Asp residue at position 48 | NOVO NORDISK A/S (DK) | 2003-04-03 | — | — | US | disclosed |
| WO-2003002569-A1 | METHOD OF INHIBITING PTP 1B AND/OR T-CELL PTP AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 | NOVO NORDISK A/S (DK) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064979-A1 | Method of inhibiting PTP 1B and /or T-cell PTP and/or other PTPases with an Asp residue at position 48 | PTPRO, PTPRF, PTPA | SLC6A3 4010/4885SLC6A2 4407/4885SLC6A4 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.